article thumbnail

Alzheimer’s therapeutics market to reach $6.8 billion by 2032

European Pharmaceutical Review

In 2015, Alzheimer’s Therapeutics International found there was an estimated 46.8 According to Alzheimer’s Therapeutics International in 2015, 58 percent of people with dementia live in developing countries, but by 2050 this will rise to 68 percent. percent, and driven largely by collaboration of existing players, reach $6.8

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.

Immunity 135
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The end-of-life care conundrum

pharmaphorum

The most prominent of such therapies are immune checkpoint inhibitors, such as the PD-1/PD-L1 therapies that have become some of the best-selling treatments across the industry. What did change was the use of chemotherapy (26% in 2015 and 16% in 2019), and the increase in the delivery of immunotherapy (5% in 2015 and 18% in 2019).

article thumbnail

Sandoz receives US FDA approval for biosimilar Hyrimoz® high-concentration formulation

LifeProNow

Since launching the first biosimilar in the US in 2015, Sandoz has proven biosimilars create early and expanded patient access to life-altering medicines while increasing healthcare savings and creating competition that fuels innovation and development of new and enhanced treatments in areas of unmet need.

article thumbnail

Ex-Merck & Co scientist accused of stealing trade secrets could face jail

pharmaphorum

Quadri, formerly Merck’s head of medical and scientific affairs, immune oncology, has been charged with one count of theft of trade secrets and one count of unauthorised transmission of trade secrets, some relating to the multi-billion dollar cancer immunotherapy Keytruda (pembrolizumab).

article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015. World Health Organization. The Global Health Observatory.

article thumbnail

IO Biotech raises $155m to develop breakthrough cancer vaccine

pharmaphorum

The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.